• Circassia Ltd., of Oxford, UK, started a pivotal, large-scale Phase III study of its ToleroMune cat allergy treatment for rhinoconjunctivitis. The study will test safety and efficacy of the ToleroMune treatment in approximately 1,200 subjects from the U.S., Canada and Europe.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter